Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez

Blood (2022) 140 (Supplement 1): 3925–3928.

https://doi.org/10.1182/blood-2022-167453

Published: 2022

Journal Articles

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Blood (2022) 140 (Supplement 1): 826–827.

https://doi.org/10.1182/blood-2022-158669

Published: 2022

Journal Articles

Metformin for Treatment of Cytopenias in Children and Young Adults with Fanconi Anemia

Blood (2021) 138 (Supplement 1): 1102.

https://doi.org/10.1182/blood-2021-153598

Published: 2021

Journal Articles

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Beatriz Rey Búa, Ana Jiménez Ubieto, MDPhD, Jose Javier Sanchez Blanco, Pau Abrisqueta, MD PhD, Antonio Gutierrez, Angel Ramirez Payer, Eva Giné, MD PhD, Izaskun Cebeiro, Sr., Maria Jose Terol, Fatima De la Cruz, MD, Rafael Andreu, María José Ramírez Sánchez, Adolfo de la Fuente, Ma Cruz Viguria, Maria Jesús Peñarrubia, Carlos Grande, Dolores Caballero, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-140786

Published: 2020

Journal Articles

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-138690

Published: 2020

Journal Articles

NHEJ-Mediated Gene Editing, a Versatile Approach to Correct a Variety of Fanconi Anemia Genes in HSCs

Francisco J Roman-Rodriguez, PhD, Laura Ugalde, Lara A. Alvarez, Begoña Díez-Cabezas, PhD, Jordi Surrallés, PhD, Maria Jose Ramirez, PhD, Massimo Bogliolo, PhD, Helmut Hanenberg, MD PhD, Julian Sevilla, MD PhD, Sandra Rodriguez-Perales, PhD, Raul Torres-Ruiz, PhD, Juan A. Bueren, PhD, Paula Rio, PhD

Blood (2019) 134 (Supplement_1): 4639.

https://doi.org/10.1182/blood-2019-129946

Published: 2019

Journal Articles

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Blood (2017) 130 (Supplement 1): 2008.

https://doi.org/10.1182/blood.V130.Suppl_1.2008.2008

Published: 2017

Journal Articles

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Blood (2017) 130 (Supplement 1): 1624.

https://doi.org/10.1182/blood.V130.Suppl_1.1624.1624

Published: 2017

Journal Articles

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

Francisco Javier Peñalver Párraga, José Antonio Márquez Navarro, Soledad Durán Nieto, Pilar Giraldo Castellano, Carlos Montalbán Sanz, María José Ramírez Sánchez, Juan-Manuel Sancho Cia, María José Terol Castera, Francisco Javier Capote Huelva, Antonio Gutiérrez García, Blanca Sánchez González, Antonio Salar Silvestre, Miguel Canales Albendea, MD PhD, María Dolores Caballero Barrigón

Blood (2016) 128 (22): 1788.

https://doi.org/10.1182/blood.V128.22.1788.1788

Published: 2016

Journal Articles

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, MD, Fatima Ibañez, MD, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, MD, Antonio Jiménez-Velasco, MD

Blood (2016) 128 (22): 1906.

https://doi.org/10.1182/blood.V128.22.1906.1906

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Blood (2016) 128 (22): 4201.

https://doi.org/10.1182/blood.V128.22.4201.4201

Published: 2016

Journal Articles

Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method

Valentín García-Gutierrez, Maria Teresa Gómez Casares, Jimenez Velasco Antonio, Alonso Juan Manuel, Santiago Osorio, Juan Carlos Hernández-Boluda, Jose Manuel Puerta, Rosa Collado, Maria Jose Ramirez, Fatima IbaÃ±ez, María Luisa Martín Mateos, Juan Diego Rodriguez Gambarte, Carolina Martinez Laperche, Sara Redondo, Montse Gomez, DV Suarez Fiallo, Alicia Rodriguez Fernandez, Concepcion Ruiz, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2776.

https://doi.org/10.1182/blood.V126.23.2776.2776

Published: 2015

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Journal Articles

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Blood (2015) 126 (23): 1514.

https://doi.org/10.1182/blood.V126.23.1514.1514

Published: 2015

Journal Articles

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

Blood (2014) 124 (21): 2524.

https://doi.org/10.1182/blood.V124.21.2524.2524

Published: 2014

Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Blood (2014) 124 (21): 5523.

https://doi.org/10.1182/blood.V124.21.5523.5523

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Blood (2014) 124 (21): 3980.

https://doi.org/10.1182/blood.V124.21.3980.3980

Published: 2014

Journal Articles

Role Of PET/CT In The Management Of Burkitt Lymphoma

Estrella Carrillo, MD, Fatima De la Cruz, Víctor Marín, María Solé, Isabel Borrego, Eduardo Quiroga, Marina Manzanares, Francisco Javier Capote, María José Ramirez, Ildefonso Espigado, Ricardo Vázquez, Pérez-Simón Jose Antonio

Blood (2013) 122 (21): 4311.

https://doi.org/10.1182/blood.V122.21.4311.4311

Published: 2013

NARROW

Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Metformin for Treatment of Cytopenias in Children and Young Adults with Fanconi Anemia

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure

NHEJ-Mediated Gene Editing, a Versatile Approach to Correct a Variety of Fanconi Anemia Genes in HSCs

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy

Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

A Phase 2 Study from Spanish Geltamo Group Investigating the Efficacy and Safety of Bendamustine As Part of Conditioning Regimen for Autologous Stem-Cell Transplantation in Patients with Aggressive Lymphomas: Second Interim Analysis

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011)

Role Of PET/CT In The Management Of Burkitt Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only